Navigation Links
Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Date:8/19/2007

Interim Phase 1 Data Confirms Safety and Tolerability

PLYMOUTH MEETING, Pa., Aug. 8 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced interim data from the first Phase 1 clinical study of trodusquemine (MSI-1436) for the treatment of obesity. Anthony DelConte, M.D., Vice President, Clinical Research and Development, presented "Trodusquemine: A Novel Aminosterol for the Treatment of Obesity and Related Metabolic Disorders," during the IBC 12th Annual World Congress on Drug Discovery & Development of Innovative Therapeutics, August 6-8 in Boston.

The presentation summarized the clinical trial design of the single ascending dose Phase 1 study of MSI-1436 to evaluate safety and pharmacokinetics of the drug in healthy obese volunteers. Dr. DelConte provided interim data from the initial cohorts in the double-blind, randomized, placebo-controlled trial which included safety and pharmacokinetic (PK) data from 20 treated subjects and eight vehicle controls in four sequential dose groups. According to Dr. DelConte, PK profiles from the study thus far show a predictable pattern with minimal subject-to-subject variability and linearity across the range of doses studied. To date, no serious adverse events have been reported. It was emphasized that further study is needed to establish dose limiting toxicity and proof-of-concept in humans.

"These initial findings validate the preclinical safety and PK work done by Genaera scientists. We are encouraged by these findings and will continue to further characterize the safety profile and provide proof of concept for trodusquemine in obesity and type 2 diabetes management," commented Jack Armstrong, President and CEO. "We anticipate a
'/>"/>

SOURCE Genaera Corporation

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company ... today announced that it has initiated dosing in a ... daily, oral therapy for the treatment of HCV infection. This ... is designed to assess both the safety and antiviral ... drug for the treatment of chronic HCV infections and ...
(Date:5/23/2013)... 23, 2013  Net Medical Xpress Solutions, Inc., (OTC ... today the company has signed a letter of intent ... in Huntsville, AL . MedTel Solutions ... staffing and recruitment of telemedicine physicians. Consideration for the ... agreement, which is expected by June 30, 2013. ...
(Date:5/23/2013)... , May 23, 2013  CAS Medical Systems, Inc. (NASDAQ: ... for non-invasive patient monitoring, today announced that Thomas ... present at the 2 nd Annual Marcum MicroCap Conference ... in New York City . ... in the Estate 10 room and will be available via ...
Breaking Medicine Technology:Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2
... , , , , , , ... MIVI-TRUST Phase III Program With Microplasmin Recruits a Total of Over,640 ... (Euronext Brussels: THR), a biopharmaceutical company,focused on the discovery and development ... that it has completed,the enrolment of the second Phase III trial ...
... , NORCROSS, Ga., Dec. 15 Immucor, Inc. (Nasdaq: ... to the blood transfusion industry, today announced that it will ... 6, 2010 after the market close. The Company will host ... a.m. (Eastern Time) to discuss the results. , ...
Cached Medicine Technology:ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4
(Date:5/23/2013)... members of the PETA International Science Consortium, Ltd., ... Safety Improvement Act of 2013: , Reform of ... also modernizes toxicity testing. , Ensuring the ... important goal. Reforming the EPA,s Toxic Substances ... the National Research Council,s vision for transforming toxicity ...
(Date:5/23/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) -- ... save an infant born with a serious airway malformation sheds ... and surgery. A report in the May 23 ... sparked the innovation. At first, the baby born five ... difficulty breathing and eating when he was 6 weeks old. ...
(Date:5/23/2013)... Located at 22343 La Palma Ave. #125, ... its Grand Opening Family Fun Charity event on May 11, ... and physical fitness. Sponsored by many different vendors like Chick-fil-a ... filled Grand Opening featured mini boot camp sessions and raffled ... the Yorba Linda fitness center has to offer. ...
(Date:5/23/2013)... 2013 Angeline Jolie’s brave decision to have ... was an 87% chance she would develop breast cancer is ... cancer. Long term studies show American women have a 12 ... , Among the things that can be changed to ... drink a day) smoking, and avoiding becoming obese. Choice of ...
(Date:5/23/2013)... TX (PRWEB) May 23, 2013 With rates ... people are searching for answers on how to lose weight. ... of going under the knife in an attempt to shed ... can be significantly outweighed by the negative health consequences that ... concern to consider before undergoing invasive surgery, colon cancer. ...
Breaking Medicine News(10 mins):Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 3Health News:Yorba Linda Personal Trainer Celebrates Fit Body Boot Camp Yorba Linda Grand Opening by Hosting a Family Fun Charity Event 2Health News:Yorba Linda Personal Trainer Celebrates Fit Body Boot Camp Yorba Linda Grand Opening by Hosting a Family Fun Charity Event 3Health News:Angelina Jolie has Women Asking for Ways to Reduce the Risk of Breast Cancer 2Health News:hCGTreatments/Diet Doc hCG Diet & Weight Loss Plans Now Teach Patients How to Lose Weight Safely and Offer Alternative to Weight Loss Surgery Now Linked to Colon Cancer 2Health News:hCGTreatments/Diet Doc hCG Diet & Weight Loss Plans Now Teach Patients How to Lose Weight Safely and Offer Alternative to Weight Loss Surgery Now Linked to Colon Cancer 3
... Medical Innovations, Inc. (NYSE: IMA ), a global ... at home through the merger of rapid diagnostics and health ... 2009 earnings on Monday, April 27, 2009. The Company will ... Time) on that date to discuss these results and other ...
... Ohio An experimental agent has shown promising results ... multi-institutional clinical trial led by cancer researchers at the ... AZD6244 (ARRY-142886), blocks certain enzymes that cancer cells need ... diagnosed with biliary cancer worldwide every year, representing 15-20 ...
... very difficult choices, such as deciding to end life-support for ... Journal of Consumer Research delves into the question of ... make those "tragic choices." , Authors Simona Botti (London ... University) say that from the time of Hippocrates until the ...
... vending machines offer healthy choices these days, so why do ... Journal of Consumer Research shows that some efforts ... have fulfilled a healthy eating goal even if they choose ... among food choices may draw their attention to the least-healthy ...
... WASHINGTON, April 20 Mark Leventhal, Esq., the Founder and ... first in the nation executive weight loss consulting service for ... Angeles County Bar Association, 1055 West 7th Street, 27th Floor, ... in 2009." Mark Leventhal will be talking about ...
... In an unprecedented effort to increase access to ... people with disabilities, President Obama invited CEOs from ... Tobin, United Spinal Association,s President ( www.unitedspinal.org ... briefing on the Administration,s disability policy initiatives, and ...
Cached Medicine News:Health News:Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 27, 2009 to Discuss First Quarter 2009 Results 2Health News:Targeted agent shows promise in biliary cancer study 2Health News:Tragic choices: Is it better for doctors or patient families to decide? 2Health News:Best intentions: The presence of healthy food can lead to unhealthy choices 2Health News:Mark Leventhal Speaks at the Los Angeles County Bar Association 2Health News:United Spinal Association Joins National Disability Leaders for Historic Meeting at the White House 2
The major innovation in posterior stabilized (PS) knee design. Improve patellofemoral kinematics. Reduce wear rate potential. Increase resistance to posterior tibial dislocation. Achieve at least 120...
... uni-compartmental knee replacement is an exciting development ... procedure provides patients with a minimally invasive ... the knee often results in severe pain, ... life and even depression. Orthopedic surgeons have ...
... total knee prosthesis stems from many years ... and manufacturing technologies have been used in ... well as a favorable pressure distribution pattern ... wear to a minimum. The inherent design ...
Cemented hip system...
Medicine Products: